{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:35:09Z","timestamp":1786394109437,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacc.2026.03.026","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:34:16Z","timestamp":1773664456000},"page":"3559-3569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure"],"prefix":"10.1016","volume":"87","author":[{"given":"Yasuhiro","family":"Hamatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.03.026_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","article-title":"Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM","volume":"9","author":"Lewis","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF Trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib6","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.026_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cardfail.2025.02.014","article-title":"JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure","volume":"31","author":"Kitai","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib9","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.026_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cardfail.2024.09.010","article-title":"The psychometric performance of the Kansas City Cardiomyopathy Questionnaire-12 in symptomatic obstructive hypertrophic cardiomyopathy","volume":"31","author":"Sauer","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib14","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jacc.2024.06.036","article-title":"Effects of sotagliflozin on health status in patients with worsening heart failure: results from SOLOIST-WHF","volume":"84","author":"Bhatt","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib15","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study","volume":"42","author":"Jankowska","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.026_bib16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the Global Congestive Heart Failure Study of 23 000 Patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.026_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/circoutcomes.11.suppl_1.203","article-title":"Health status variation across practices in outpatients with heart failure: insights from the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry","volume":"11","author":"Khariton","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.026_bib18","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jacc.2025.03.545","article-title":"Predicting heart failure outcomes using patient-reported health status: real-world validation of the KCCQ-12","volume":"85","author":"El-Sabawi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib22","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.026_bib24","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.026_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamacardio.2023.1342","article-title":"Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the DELIVER Trial","volume":"8","author":"Peikert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jchf.2023.04.016","article-title":"Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction","volume":"11","author":"Butt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF Trial","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.026_bib28","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ejhf.2738","article-title":"Health-related quality of life outcomes in PARAGON-HF","volume":"24","author":"Chandra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.026_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54084","article-title":"Electronic patient-reported outcome system implementation in outpatient cardiovascular care: a randomized clinical trial","volume":"8","author":"Yamashita","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.026_bib30","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.124.069624","article-title":"Clinical impact of routine assessment of patient-reported health status in heart failure clinic: the PRO-HF Trial","volume":"149","author":"Sandhu","year":"2024","journal-title":"Circulation"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972605744X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972605744X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:26:09Z","timestamp":1786393569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972605744X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S073510972605744X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.026","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}